<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Riddle, Matthew C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Insulin Glargine Formulation Associated with Less Nocturnal Hypoglycemia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-26</style></pages><abstract><style  face="normal" font="default" size="100%">A long-acting basal insulin glargine formulation, 300 U/mL (Gla-300), controlled glycemia as well as insulin glargine 100 U/mL (Gla-100) in patients with type 2 diabetes mellitus (T2DM) but with less nocturnal hypoglycemia. This article presents findings from a Phase 3 multicenter, open-label [EDITION I; NCT01499082] study comparing the two insulin glargine formulations in patients with T2DM who were using basal plus mealtime insulin.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>